Prognostic significance of early tumor shrinkage in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based combination therapy
Early tumor shrinkage predicts longer survival in kidney cancer patients on immunotherapy, helping doctors decide whether to continue current treatments.
In 169 mRCC patients across multiple Japanese institutions, early tumor shrinkage at first imaging assessment was independently associated with overall survival in multivariate analysis across multiple ICI-based combination regimens. These findings suggest early tumor shrinkage could serve as a practical surrogate endpoint and prognostic indicator, providing actionable guidance on treatment continuity decisions.
What the study was
- Study design
- Retrospective multicenter cohort study
- Population
- 169 mRCC patients treated with first-line ICI-based combination therapy (nivolumab+ipilimumab, pembrolizumab+axitinib, pembrolizumab+lenvatinib, nivolumab+cabozantinib)
- Sample size
- 169
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Int J Clin Oncol
Why it surfaced
Multicenter Japanese cohort providing real-world evidence that early tumor shrinkage predicts OS in mRCC ICI therapy. Retrospective; finding while clinically useful is incremental.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.